Colorectal cancer remains a "silent killer" due to late-stage diagnosis. JelloX Biotech, a Taiwanese startup, is addressing the limitations of traditional 2D pathology—where thin tissue slices can miss high-risk regions—with its patented 3D Intelligent Pathology technology.

• Technical Superiority: By utilizing tissue clearing combined with AI analysis, JelloX provides over 200 times more tissue information than traditional 2D pathology. This allows clinicians to view the entire 3D structure of a lesion, including vascular and immune cell distribution.
• Clinical Impact: Data indicates that 3D pathology can identify high-risk features in approximately 40% of cases previously classified as "low risk" by 2D methods, enabling earlier intervention.
• U.S. Expansion: JelloX has secured FDA (U.S.) and TFDA (Taiwan) Class II medical device clearances and has processed over 2,000 cases across colorectal, breast, and lung cancers. The company has established its first overseas Central Lab in Phoenix, Arizona, and has initiated a collaboration with the Mayo Clinic.
• Recognition: Phoenix Mayor Kate Gallego publicly commended JelloX as a premier example of Taiwanese innovation succeeding in Arizona’s burgeoning medtech ecosystem. The 3D pathology market for polyp diagnosis and HER2 testing is projected to exceed $10 billion by 2030.

Resource: 捷絡生技靠「3D病理」打進美國醫療核心